Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.

The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.

Global data are in the same ballpark as Chinese results presented earlier this year.

It’s a new term for biotech and its investors.

China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.

LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.